预约演示
更新于：2025-01-01
Loxoprofen Sodium Hydrate
洛索洛芬钠
更新于：2025-01-01
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C15H20NaO4 |
InChIKeyNGHFIMBWFYJBHQ-UHFFFAOYSA-N |
CAS号226721-96-6 |
关联
103
项与 洛索洛芬钠 相关的临床试验CTR20244576
在中国健康受试者中随机、开放、两周期、双交叉餐后状态下洛索洛芬钠控释片与洛索洛芬钠片药代动力学比较试验
CTR20243833
洛索洛芬钠凝胶贴膏治疗膝骨关节炎疼痛的有效性和安全性的多中心、随机、阳性药/安慰剂平行对照临床试验
CTR20243556
洛索洛芬纳贴剂人体生物等效性研究
100 项与 洛索洛芬钠 相关的临床结果
登录后查看更多信息
100 项与 洛索洛芬钠 相关的转化医学
登录后查看更多信息
100 项与 洛索洛芬钠 相关的专利（医药）
登录后查看更多信息
622
项与 洛索洛芬钠 相关的文献（医药）2025-01-01ARCHIVES OF ORAL BIOLOGY
Effects of loxoprofen on impaired water-evoked swallows in a pharyngitis rat model
Article
作者: Hsu, Chia-Chien ; Nakatomi, Chihiro ; Ono, Kentaro ; Tsuji, Keiko ; Fukuzaki, Mari ; Shimada, Tomoki ; Kawamoto, Tatsuo ; Kubo, Sayaka
OBJECTIVE:
The objective of this study was to investigate the effects of nonsteroidal anti-inflammatory drugs (NSAIDs; e.g., loxoprofen) on pharyngitis-induced dysphagia in rats.
DESIGN:
A pharyngitis rat model was generated by topical application of acetic acid to the laryngopharyngeal region. Changes in water swallowing were evaluated by endoscopic observation over time. A histological analysis of the laryngopharyngeal mucosa was performed. The effects of loxoprofen, antibacterial drugs, and transient receptor potential (TRP) channel inhibitors were investigated in model rats.
RESULTS:
After acetic acid treatment, water-evoked swallowing was impaired on day 1 (prolonging the swallowing latency and interval and decreasing the number of swallows), and recovered until day 6. Administration of loxoprofen significantly alleviated impaired water swallowing. Histologically, loxoprofen significantly improved inflammation of the pharynx, including submucosal edema, but did not affect the loss of taste bud-like structures in the arytenoid. In contrast, the administration of antibacterial drugs or TRP channel inhibitors did not affect the impairment of water swallowing in the model group.
CONCLUSION:
These results demonstrate the efficacy of systemic administration of loxoprofen in improving swallowing impairment in a pharyngitis model rat. This study is the first to provide scientific evidence for the use of NSAIDs in the management of pharyngitis.
2024-12-01Bulletin of the Hospital for Joint Diseases
Leukocyte-Poor Platelet-Rich Plasma as a Treatment for Patellar Tendinopathy A Multicenter, Randomized Controlled Trial.
Article
作者: Weinberg, Maxwell ; Bloom, David A ; Strauss, Eric J ; Pham, Hien ; Wasterlain, Amy ; Dragoo, Jason L ; Herrero, Christina
PURPOSE:
The purpose of this study was to compare regimens of eccentric exercise and dry-needling, with and without an ultrasound-guided leukocyte-poor platelet-rich plasma (LP-PRP) injection, in patients with patellar tendinopathy.
METHODS:
Patients with symptomatic patellar tendinopathy based on physical examination and magnetic resonance imaging and who had failed at least 6 weeks of nonoperative treatment were enrolled and randomized at two centers to receive ultrasound-guided dry-needling (DN) alone or in addition to an injection of LP-PRP coupled with standardized eccentric strengthening exercises. Participants completed patient-reported outcome surveys at baseline and at 3, 6, 9, 12, and 26 weeks post-treatment. The primary outcome measure was the Victorian Institute of Sports Assessment (VISA) score for patellar tendinopathy (VISA-P) at 12 weeks, and secondary measures included the visual analog scale (VAS) for pain, Tegner activity scale, Lysholm knee scale (Lysholm), and Veterans Rand 12-Item Health Survey (VR12) questionnaire at 12 and 26 weeks.
RESULTS:
Thirty-one subjects were enrolled in the study (15 DN, 16 LP-PRP). Twenty-three patients were available for follow-up at all time points. There were no statistically significant differences between the two groups at baseline. At 12 weeks post-treatment, both the LP-PRP and DN groups demonstrated statistically significant (p < 0.05) improvements from baseline with respect to Lysholm score (34.5 ± 15.1 and 31.7 ± 18.4), VAS pain scale (-1.58 ± 2.1 and -2.8 ± 1.9, respectively), and VISA score (19.2 ± 15.9 and 28.4 ± 19.4, respectively). At 26 weeks post-treatment both groups demonstrated statistically significant (p < 0.05) improvements in Lysholm score (23.6 ± 23.1 and 24.5 ± 17.3, respectively) and VAS pain score (-1.67 ± 2.3 and -2.18 ± 2.9, respectively). The LP-PRP group failed to show significance for VISA-P score from 0 to 26 weeks, though the DN group did (22.0 ± 14.6). There were no statistically significant differences between the two groups in mean VISA, VAS, Lysholm, or the Short Form Health Survey (SF-12) scores at either the 12 week or 26-week follow-up time points.
CONCLUSION:
The results of the current study demonstrate that both DN and DN plus LP-PRP are effective treatment options in the management of symptomatic patellar tendinopathy, however, LP-PRP did not add any additional improvement over DN alone.
2024-12-01Integrative Medicine Research
Clinical research on the effectiveness and safety of Uchasingihwan for low back pain with radiculopathy caused by herniated intervertebral disc of the lumbar spine: A multicenter, randomized, controlled equivalence trial
Article
作者: Park, Yeon-Cheol ; Nam, Sang-Soo ; Kim, Jung-Hyun ; Seo, Byung-Kwan ; Goo, Bonhyuk ; Lee, Hyun-Jong ; Kim, Eun-Jung ; Nam, Dongwoo ; Baek, Yong-Hyeon ; Kim, Jae-Soo
Background:
This study aimed to establish the clinical evidence regarding the effectiveness and safety of Uchasingihwan (UCSGH) in improving pain, function, and quality of life in patients with lumbar herniated intervertebral disc (LHIVD).
Methods:
This was a multicenter, randomized, controlled, equivalence trial with two parallel arms. Seventy-four participants with LHIVD were recruited and randomly allocated to the experimental and control groups. The participants in each group took 2.5 g of UCSGH granule or loxoprofen 60 mg tablet three times a day for six weeks. Additionally, both groups received the same acupuncture treatment once a week for six weeks. Outcomes about effectiveness and safety were assessed at baseline and 3, 6, and 10 weeks after screening.
Results:
As the primary outcome, the mean differences with a 95 % confidence interval (CI) of changes in low back pain between the two groups at weeks 6 (95 % CI:9.26, 8.37) and 10 (95 % CI:9.03, 9.62) from baseline were within the equivalence limit. Also, changes in radiating pain at weeks 6 (95 % CI:1.70, 15.69) and 10 (95 % CI:4.72, 13.75) were within the equivalence limit. Outcome measures for function and quality of life also showed no statistical difference. Regarding safety, the frequency of adverse events related to intervention was lower in UCSGH.
Conclusion:
UCSGH showed the equivalent level of effectiveness as loxoprofen in reducing low back and radiating pain in LHIVD patients and showed sufficient safety to be used as a complementary treatment option.
Trial registration:
ClinicalTrials.gov (NCT03386149), CRIS (KCT0002848).
100 项与 洛索洛芬钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 术后疼痛 | 韩国 | 2024-04-03 | |
| 炎症 | 日本 | 1986-03-01 | |
| 疼痛 | 日本 | 1986-03-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 术后炎症 | 临床3期 | 中国 | 2024-04-11 | |
| 术后炎症 | 临床3期 | 中国 | 2024-04-11 | |
| 膝关节炎 | 临床3期 | 中国 | 2017-04-10 | |
| 创伤和损伤 | 临床3期 | 巴西 | 2015-10-01 | |
| 眼部炎症 | 临床2期 | 中国 | 2022-12-30 | |
| 眼部炎症 | 临床2期 | 中国 | 2022-12-30 | |
| 肌痛 | 临床2期 | 美国 | 2015-10-01 | |
| 急性支气管炎 | 临床1期 | 中国 | 2024-12-27 | |
| 急性上呼吸道炎症 | 临床1期 | 中国 | 2024-12-27 | |
| 镇痛 | 临床1期 | 中国 | 2024-12-27 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | - | 39 | (Transdermal Estradiol Plus Spironolactone) | 獵窪選獵構夢淵夢鏇憲(願鏇廠繭願製蓋蓋遞淵) = 夢鏇鑰壓鬱選選積夢醖 遞簾醖鹹糧衊獵築鹹製 (衊憲選膚鏇醖選積選範, 齋遞鹽築夢製製憲壓膚 ~ 餘鹽鏇繭糧廠壓網夢膚) 更多 | - | 2024-11-26 | |
(Daily Sublingual Estradiol Plus Spironolactone) | 獵窪選獵構夢淵夢鏇憲(願鏇廠繭願製蓋蓋遞淵) = 積簾築鬱築遞顧積壓範 遞簾醖鹹糧衊獵築鹹製 (衊憲選膚鏇醖選積選範, 鑰觸壓選顧膚鹹夢艱壓 ~ 遞獵顧鹽廠鏇壓窪醖醖) 更多 | ||||||
N/A | 451 | (People living with HIV) | 製網醖憲憲壓製選廠壓(齋夢餘襯壓願鏇蓋襯網) = 廠遞鑰糧遞獵淵觸醖壓 積淵鏇鹽獵膚蓋憲範窪 (簾顧淵願構範憲簾廠構, 5.1 ~ 36) | - | 2022-01-01 | ||
临床2期 | 47 | (Experimental) | 鑰願襯鏇積夢襯蓋襯糧(獵積鑰餘鏇構簾繭築簾) = 鏇蓋觸遞餘網簾鹹鏇鬱 醖獵糧獵製鹹蓋選壓鏇 (積齋鏇繭製築構觸遞鬱, 夢壓蓋鹽鹹觸餘醖鏇艱 ~ 醖膚餘選醖範簾壓廠選) 更多 | - | 2019-09-09 | ||
(Placebo Comparator) | 鑰願襯鏇積夢襯蓋襯糧(獵積鑰餘鏇構簾繭築簾) = 夢積遞鹽選鹹範築糧鹽 醖獵糧獵製鹹蓋選壓鏇 (積齋鏇繭製築構觸遞鬱, 艱蓋構構鑰製願憲顧艱 ~ 顧廠積襯鏇鹹築襯獵夢) 更多 | ||||||
临床3期 | 80 | 範選鏇遞餘鹽選窪餘窪(淵獵膚範積廠製積鑰壓) = 鑰齋壓憲憲淵鑰餘壓獵 鏇簾選網夢餘鑰醖遞顧 (觸選簾齋積廠築鹽蓋願, 鬱範遞鏇選餘願構廠構 ~ 壓選觸糧鬱製選糧蓋遞) 更多 | - | 2018-07-20 | |||
N/A | 70 | Loxoprofen sodium hydrogel patch (LX-P) | 鹽淵構艱衊構襯蓋鹹願(壓壓窪製鑰窪齋糧鏇遞) = 膚鬱齋鏇鏇積醖膚獵壓 遞餘窪願獵願鑰齋壓製 (淵積選鏇繭膚網艱積構 ) | 积极 | 2016-06-08 | ||
Loxoprofen sodium tablet (LX-T) | 鹽淵構艱衊構襯蓋鹹願(壓壓窪製鑰窪齋糧鏇遞) = 簾憲鹽觸觸獵淵繭鏇鹽 遞餘窪願獵願鑰齋壓製 (淵積選鏇繭膚網艱積構 ) | ||||||
临床4期 | 一线 | 190 | Celecoxib 100 mg b.d. | 蓋蓋繭蓋壓壓襯淵蓋遞(壓願鬱廠鏇鏇繭醖範觸) = 襯衊夢壓窪製鹽窪窪製 餘壓鹽齋壓願鹽選襯鹹 (獵壓齋膚築鬱獵襯積選 ) | 积极 | 2013-02-01 | |
Loxoprofen 60 mg t.d.s. | 蓋蓋繭蓋壓壓襯淵蓋遞(壓願鬱廠鏇鏇繭醖範觸) = 積築齋蓋觸廠選簾淵窪 餘壓鹽齋壓願鹽選襯鹹 (獵壓齋膚築鬱獵襯積選 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用